Vaxart, Inc. (Nasdaq: VXRT) today encourages its stockholders
of record on April 28, 2023, to vote on its proxy if they have not
yet done so. The Company urges a yes vote on all Proxy proposals.
Leading proxy advisors ISS and Glass Lewis are both advising
shareholders to vote in favor of all proposals.
Currently, all proposals are supported by a
majority of shares already voted. However, the required quorum of
voting shares representing 50% of outstanding has not been met.
Vaxart asks that all shareholders vote their
proxy, no matter how many shares they own. Stockholders of record
on April 28, 2023, may vote their shares or change their votes in
favor of all Proxy Proposals if their ballots are cast by the
deadline of Sunday, June 25, 2023, at 11:59 p.m. Eastern Time.
Stockholders of record on April 28, 2023, are
encouraged to vote over the internet at (1)
http://www.proxyvote.com, (2) by telephone by calling the toll-free
number (800) 690-6903, or (3) if you elected to receive printed
proxy materials by mail, by marking, dating, and signing your proxy
card and returning it in the accompanying postage-paid
envelope.
Vaxart’s 2023 Annual Meeting of Stockholders
will be held on Monday, June 26, 2023, at 1:00 p.m. Eastern
Time.
Stockholders of Vaxart are also urged to read
the definitive proxy statement on Schedule 14A filed by Vaxart with
the U.S. Securities and Exchange Commission (SEC) on April 28,
2023, and all other relevant documents filed with the SEC for
important information about the Proxy proposals to be voted on at
the Annual Meeting.
About VaxartVaxart is a
clinical-stage biotechnology company developing a range of oral
recombinant vaccines based on its proprietary delivery platform.
Vaxart vaccines are designed to be administered using pills that
can be stored and shipped without refrigeration and eliminate the
risk of needle-stick injury. Vaxart believes that its proprietary
pill vaccine delivery platform is suitable to deliver recombinant
vaccines, positioning the company to develop oral versions of
currently marketed vaccines and to design recombinant vaccines for
new indications. Vaxart’s development programs currently include
pill vaccines designed to protect against norovirus, coronavirus,
seasonal influenza, and respiratory syncytial virus (RSV), as well
as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s
first immune-oncology indication. Vaxart has filed broad domestic
and international patent applications covering its proprietary
technology and creations for oral vaccination using adenovirus and
TLR3 agonists.
Note Regarding Forward-Looking
Statements
This press release contains forward-looking
statements that involve substantial risks and uncertainties. All
statements, other than statements of historical facts, included in
this press release regarding Vaxart's strategy, prospects, plans
and objectives, results from preclinical and clinical trials and
the timing of such results, commercialization agreements and
licenses, and beliefs and expectations of management are
forward-looking statements. These forward-looking statements may be
accompanied by such words as "should," "believe," "could,"
"potential," "will," "expected," “anticipate,” "plan," and other
words and terms of similar meaning. Examples of such statements
include, but are not limited to, statements relating to Vaxart's
ability to develop and commercialize its product candidates,
including its vaccine booster products; Vaxart's expectations
regarding clinical results and trial data, and the timing of
receiving and reporting such clinical results and trial data; and
Vaxart's expectations with respect to the effectiveness of its
product candidates. Vaxart may not actually achieve the plans,
carry out the intentions, or meet the expectations or projections
disclosed in the forward-looking statements, and you should not
place undue reliance on these forward-looking statements. Actual
results or events could differ materially from the plans,
intentions, expectations, and projections disclosed in the
forward-looking statements. Various important factors could cause
actual results or events to differ materially from the
forward-looking statements that Vaxart makes, including risks and
uncertainties inherent in research and development, including the
ability to meet anticipated clinical endpoints, commencement,
and/or completion dates for clinical trials, regulatory submission
dates, regulatory approval dates, and/or launch dates, as well as
the possibility of unfavorable new clinical data and further
analyses of existing clinical data; the risk that clinical trial
data are subject to differing interpretations and assessments by
regulatory authorities; whether regulatory authorities will be
satisfied with the design of and results from the clinical studies;
decisions by regulatory authorities impacting labeling,
manufacturing processes, and safety that could affect the
availability or commercial potential of any product candidate,
including the possibility that Vaxart's product candidates may not
be approved by the FDA or non-U.S. regulatory authorities; that,
even if approved by the FDA or non-U.S. regulatory authorities,
Vaxart's product candidates may not achieve broad market
acceptance; that a Vaxart collaborator may not attain development
and commercial milestones; that Vaxart or its partners may
experience manufacturing issues and delays due to events within, or
outside of, Vaxart's or its partners' control; difficulties in
production, particularly in scaling up initial production,
including difficulties with production costs and yields, quality
control, including stability of the product candidate and quality
assurance testing, shortages of qualified personnel or key raw
materials, and compliance with strictly enforced federal, state,
and foreign regulations; that Vaxart may not be able to obtain,
maintain, and enforce necessary patent and other intellectual
property protection; that Vaxart's capital resources may be
inadequate; Vaxart's ability to resolve pending legal matters;
Vaxart's ability to obtain sufficient capital to fund its
operations on terms acceptable to Vaxart, if at all; the impact of
government healthcare proposals and policies; competitive factors;
and other risks described in the "Risk Factors" sections of
Vaxart's Quarterly and Annual Reports filed with the SEC. Vaxart
does not assume any obligation to update any forward-looking
statements, except as required by law.
Important Additional
Information
Vaxart filed a definitive proxy statement (the
“Proxy Materials”) with the SEC. This press release is not a
substitute for the Proxy Materials or any other documents that
Vaxart has filed or may file with the SEC or send to its
stockholders in connection with the Annual Meeting. BEFORE MAKING
ANY VOTING DECISION, VAXART URGES INVESTORS AND STOCKHOLDERS TO
READ THESE MATERIALS CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY
CONTAIN IMPORTANT INFORMATION ABOUT VAXART, THE ANNUAL MEETING, AND
RELATED MATTERS.
You may obtain free copies of the Proxy
Materials and all other documents filed or that will be filed with
the SEC regarding the Annual Meeting at the website maintained by
the SEC at www.sec.gov. Investors and stockholders are urged to
read the Proxy Materials and the other relevant materials before
making any voting or investment decision with respect to the
proposed transactions.
Participants in the
Solicitation
Vaxart and its directors and executive officers
and certain of its other members of management, employees, and
agents, may be deemed to be participants in the solicitation of
proxies in connection with the Annual Meeting. Information about
Vaxart’s directors and executive officers is included in Vaxart’s
filings with the SEC, including Vaxart’s Annual Report on Form 10-K
for the year ended December 31, 2022 and the Proxy Materials. These
documents can be obtained free of charge from the source indicated
above.
No Offer or Solicitation
This press release will not constitute an offer
to sell or the solicitation of an offer to sell or the solicitation
of an offer to buy any securities, nor will there be any sale of
securities in any jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of any such jurisdiction. No offering of
securities shall be made except by means of a prospectus meeting
the requirements of Section 10 of the Securities Act of 1933, as
amended.
Contacts
Vaxart Media Relations: |
Investor Relations: |
Mark Herr |
Andrew Blazier |
Vaxart, Inc. |
FINN Partners |
mherr@vaxart.com |
IR@vaxart.com |
(203) 517-8957 |
(646) 871-8486 |
|
|
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2024 to May 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From May 2023 to May 2024